TA B L E 1 Distribution of epidemiological and clinical factors among patients who did and did not have seroconversion, defined as at least one ≥4-fold rise in HAI antibody titers between acute and convalescent serum specimens.
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| Patient population and study design
The EPIC study prospectively studied the incidence and etiology of CAP in adults hospitalized at five hospitals in Chicago and Nashville between January 1, 2010 and June 30, 2012. The study has been described elsewhere. 8 Institutional review boards at each site and the CDC approved the study, and written informed consent was obtained. sion for pathogen detection and tested using multiple modalities.
Patients included in this analysis were hospitalized, had radiographically confirmed pneumonia, and a naso/oropharyngeal (NP/ OP) swab negative for influenza by PCR. Acute (collected upon enrollment) and convalescent (obtained 3-10 weeks after enrollment) sera were tested for hemagglutination inhibition (HAI). Patients were also required to have received influenza vaccination during the current hospitalization (≥2 weeks before collection of convalescent serum).
| Laboratory studies
Hemagglutination inhibition assays using standardized methods were performed on paired sera for the following strains circulat- 
| Statistical methods
Descriptive statistics included number (%) and median (interquartile range, IQR) for categorical and continuous variables, respectively.
Demographic and clinical characteristics were compared between seroconversion and non-seroconversion groups using Pearson's chisquare test for categorical variables and Wilcoxon rank-sum test for continuous variables.
To identify variables associated with non-seroconversion in a setting with a relatively large number of covariates but a limited number of observations, we first identified a subset of potential variables using a least absolute shrinkage and selection operator approach (lasso) regression strategy. 11 We then applied a multivariable logistic regression approach to assess the association between the subset of factors identified by the lasso, and the probability of non-seroconversion. 12 The study covariates evaluated in the lasso regression were age, gender, diabetes mellitus, smoking status, asthma, liver disease, kidney disease, cardiac disease, HIV, immunosuppression, 13 
| RE SULTS
| Patient population
Among the 2320 adults with radiographic pneumonia enrolled in the 
| Factors associated with non-seroconversion
In comparison with patients who seroconverted, patients who did not seroconvert were more likely to have diabetes mellitus (P = 0.033) and a baseline HAI ≥ 40 for influenza B (Yamagata, P = 0.026) in bivariate analyses (Table 1) with non-seroconversion after in-hospital influenza vaccination (Table 2 ).
| Seroconversion to individual influenza strains
Sixty-six (69%, 95% CI 59%-79%) of these 95 patients seroconverted to ≥1 influenza virus strain: 44% to influenza A(H1N1)pdm09, 46% to influenza A(H3N2), 34% to influenza B (Victoria), and 22% to influenza B (Yamagata). Seropositive titers after vaccination were achieved in 55%
(95% CI 45-65) of patients to influenza A(H1N1)pdm09, 58% (95% CI 48-68) to influenza A(H3N2), 77% (95% CI 68, 86) to influenza B (Victoria), and 74% (95% CI 665, 83) to influenza B (Yamagata) viruses (Table 3) .
Among those with a baseline HAI titer ≥ 40 for individual strains, after vaccination 35% (8/23) of these individuals developed a ≥ 4 fold HAI rise to influenza A(H1N1)pdm09, 29% (7/24) to influenza A(H3N2), 8% (3/37) to influenza B (Victoria), and 14% (8/56) to influenza B (Yamagata).
| D ISCUSS I ON
Influenza vaccination during CAP hospitalization resulted in seroconversion to ≥1 influenza virus strains in 69% of the 95 patients.
We lacked a directly comparable control group of non-hospitalized adults, but overall seroconversion rates observed here were suboptimal. We had anticipated that age, mild immunosuppression, or measures of CAP severity (eg, PSI score, duration of hospitalization, and ICU admission) might explain differences in seroconversion, but these associations were not observed (Table 1) . Prior receipt of influenza vaccine and diabetes has been previously identified as risk factors for non-seroconversion after influenza vaccination in people who were not acutely ill.
3,4
Seropositive titers were achieved for >50% of influenza A strains and about 75% of influenza B strains following vaccination.
Importantly, this was shortly after inclusion of the new influenza
A(H1N1)pdm09 strain in the vaccine. More potent vaccines could improve immunogenicity among adults at risk of poor serological responses. High-dose influenza vaccine is licensed by the US Food and Drug Administration (FDA) and is recommended for prevention TA B L E 2 Adjusted odds ratios (OR) with 95% confidence intervals (CI) for non-seroconversion to any influenza strain after influenza vaccination Estimates in this study lack some statistical power to detect differences between the groups due to the small sample size. Finally, due to the small numbers, the immune responses were evaluated in aggregate rather than examining responses to each antigen separately.
Despite a lower seroconversion rate after influenza vaccination for adults who received the vaccine during an acute hospitalization for CAP than might be observed among healthy adult outpatients, hospitalization represents an important opportunity to vaccinate patients who may not return for vaccination after discharge; and almost 70% of our study patients did seroconvert to ≥1 strain. 
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